TELA Bio, Inc. (TELA) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, TELA Bio reported revenue of $80.3M, up 15.8% from $69.3M the year before. Net income was -$38.8M (a -48.4% net margin), or -$0.83 per diluted share. Gross margin was 67.7% and operating margin was -42.0%. Operating activities generated -$28.2M of cash, leaving -$28.7M of free cash flow. At fiscal year end, TELA Bio held $81.4M in total assets against $75.1M in total liabilities, including $50.8M of cash and equivalents.
Open the full interactive TELA Bio financials → Quarterly statements, key ratios, valuation history and price charts.
TELA Bio Key Stats
| Share Price | $1.07 |
|---|---|
| Market Cap | $61.1M |
| Revenue YoY Growth | +15.8% |
| 52-Week Range | $0.56 – $1.53 |
| Shares Outstanding | 57.4 million (basic, 2026 Q2) |
TELA Bio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $18.2M | $29.5M | $41.4M | $58.5M | $69.3M | $80.3M |
| Gross Profit | $11.2M | $18.8M | $27.0M | $40.1M | $46.5M | $54.3M |
| Operating Income | -$25.3M | -$29.5M | -$39.0M | -$44.1M | -$34.1M | -$33.8M |
| Pre-Tax Income | -$28.8M | -$33.3M | -$44.3M | -$46.7M | -$38.0M | -$38.6M |
| Income Tax | — | — | — | — | -$144,000 | $230,000 |
| Net Income | -$28.8M | -$33.3M | -$44.3M | -$46.7M | -$37.8M | -$38.8M |
| Diluted EPS | -$2.23 | -$2.30 | -$2.72 | -$2.04 | -$1.33 | -$0.83 |
TELA Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $20.7M | $20.9M | $19.1M | $19.3M |
| Net Income | -$8.6M | -$9.0M | -$12.3M | -$11.3M |
| Diluted EPS | -$0.19 | -$0.19 | -$0.21 | -$0.20 |
TELA Bio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $74.4M | $43.9M | $42.0M | $46.7M | $52.7M | $50.8M |
| Current Assets | $83.2M | $59.1M | $62.4M | $71.7M | $78.1M | $75.6M |
| Total Assets | $86.5M | $62.5M | $67.9M | $78.0M | $86.6M | $81.4M |
| Current Liabilities | $6.6M | $10.6M | $12.4M | $17.0M | $15.6M | $18.0M |
| Total Long-Term Debt | $30.8M | $31.5M | $39.9M | $40.5M | $41.1M | $55.7M |
| Total Liabilities | $37.4M | $42.4M | $53.5M | $59.2M | $58.1M | $75.1M |
| Shareholders' Equity | $49.0M | $20.1M | $14.3M | $18.9M | $28.5M | $6.3M |
TELA Bio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$24.5M | -$30.4M | -$40.7M | -$40.9M | -$41.6M | -$28.2M |
| Cash From Investing | $9.1M | -$627,000 | -$1.9M | -$599,000 | $4.5M | $846,000 |
| Cash From Financing | $44.4M | $585,000 | $40.9M | $46.3M | $43.1M | $25.8M |
| Free Cash Flow | -$24.6M | -$31.1M | -$41.6M | -$41.5M | -$42.6M | -$28.7M |
Figures from TELA Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TELA Bio financials page for every line item.
TELA Bio Company Profile
| Ticker | TELA |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Malvern, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001561921 |
Frequently Asked Questions
What was TELA Bio's revenue in fiscal 2025?
TELA Bio (TELA) reported revenue of $80.3M for fiscal 2025.
What is TELA Bio's annual revenue history?
TELA Bio's annual revenue by fiscal year: 2020: $18.2M; 2021: $29.5M; 2022: $41.4M; 2023: $58.5M; 2024: $69.3M; 2025: $80.3M.
What was TELA Bio's net income in fiscal 2025?
TELA Bio reported net income of -$38.8M for fiscal 2025.
What was TELA Bio's earnings per share (EPS) in fiscal 2025?
TELA Bio's diluted EPS was -$0.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did TELA Bio generate in fiscal 2025?
TELA Bio generated -$28.7M of free cash flow in fiscal 2025.
What was TELA Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), TELA Bio reported revenue of $19.3M.
How much debt does TELA Bio have?
TELA Bio reported $55.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of TELA Bio are outstanding?
TELA Bio reported a weighted average of 57.4 million basic shares outstanding in 2026 Q2.
What is TELA Bio's market cap?
Based on its latest closing price, TELA Bio (TELA) has a market capitalization of about $61.1M.
When does TELA Bio's fiscal year end?
TELA Bio's fiscal year end, as registered with the SEC, is December 31.
Where is TELA Bio headquartered?
TELA Bio lists its business address in Malvern, Pennsylvania in its SEC filings.